ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.（ACAD）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ACAD · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
21
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
ACADIA Pharmaceuticals Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
ACAD 季度内部人买卖趋势
ACAD 内幕交易卖出 · ACAD 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · ACAD CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ACAD 高管卖出股份 · ACAD 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 29, 2026 | BAKER BROS. ADVISORS LP Director | Award | 18,622 | — | Form 4 |
| May 29, 2026 | BAKER BROS. ADVISORS LP Director | Award | 18,622 | — | Form 4 |
| May 29, 2026 | HARRIGAN EDMUND Director | Option | 8,107 | — | Form 4 |
| May 29, 2026 | Ndu Adora Director | Option | 8,107 | — | Form 4 |
| May 29, 2026 | Brege Laura Director | Option | 8,107 | — | Form 4 |
| May 29, 2026 | Poole Jonathan Director | Option | 2,010 | — | Form 4 |
| May 29, 2026 | GAROFALO ELIZABETH A. Director | Option | 8,107 | — | Form 4 |
| May 29, 2026 | Daly James M Director | Option | 8,107 | — | Form 4 |
| May 26, 2026 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Sale | 5,401 | $114K | Form 4 |
| May 1, 2026 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Option | 2,596 | — | Form 4 |
| May 4, 2026 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Sale | 1,332 | $29K | Form 4 |
| May 1, 2026 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option | 6,815 | — | Form 4 |
| May 4, 2026 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Sale | 3,506 | $76K | Form 4 |
| Apr 5, 2026 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Option | 5,276 | — | Form 4 |
| Apr 7, 2026 | Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER | Sale | 2,709 | $60K | Form 4 |
| Apr 5, 2026 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Option | 2,010 | — | Form 4 |
| Apr 7, 2026 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Sale | 1,030 | $23K | Form 4 |
| Mar 24, 2026 | Owen Adams Catherine CEO · Director | Option | 23,509 | — | Form 4 |
| Mar 25, 2026 | Owen Adams Catherine CEO · Director | Sale | 11,641 | $250K | Form 4 |
| Mar 24, 2026 | Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC | Option | 7,515 | — | Form 4 |
| Mar 25, 2026 | Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC | Sale | 3,844 | $83K | Form 4 |
| Mar 24, 2026 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Option | 6,715 | — | Form 4 |
| Mar 25, 2026 | Thompson Elizabeth H.Z. EVP, Head of Research & Dev | Sale | 3,435 | $74K | Form 4 |
| Mar 25, 2026 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Option | 2,142 | — | Form 4 |
| Mar 26, 2026 | Kihara James PRINCIPAL ACCOUNTING OFFICER | Sale | 1,097 | $24K | Form 4 |
Rhodes Jennifer J
EVP, CHIEF LEGAL OFFICER, SEC
日期
Mar 25
股数
3,844
均价
$21.47
总金额
$83K
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev
日期
Mar 24
股数
6,715
均价
—
总金额
—
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev
日期
Mar 25
股数
3,435
均价
$21.47
总金额
$74K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ACAD 内幕交易
ACAD 内幕交易
ACADIA Pharmaceuticals Inc.（ACAD）内幕交易数据来源于公司内部人（包括Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER), Kihara James (PRINCIPAL ACCOUNTING OFFICER), Rhodes Jennifer J (EVP, CHIEF LEGAL OFFICER, SEC)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ACAD内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看ACADIA Pharmaceuticals Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ACAD 内幕交易 · 5个问题ACADIA Pharmaceuticals Inc.（ACAD）的内部人包括高管和董事，如Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER), Kihara James (PRINCIPAL ACCOUNTING OFFICER), Rhodes Jennifer J (EVP, CHIEF LEGAL OFFICER, SEC)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026